Advantages for Gilead's potential HIV blockbuster TAF in interim Phase II data
This article was originally published in Scrip
Executive Summary
Gilead Sciences appears to be making good progress toward extending the life of its multibillion-dollar HIV franchise with positive data reported on 31 October from the half-way point of its ongoing 48-week Phase II clinical trial for tenofovir alafenamide fumarate (TAF; formerly GS-7340), a nucleotide reverse transcriptase inhibitor and novel prodrug of tenofovir, the active ingredient in the company's Viread (tenofovir disoproxil fumarate (TDF)).